Overview

Safety and Tolerability of IDO-1 Inhibition in the Prevention of EBV-related Pathology in EBV Negative Kidney Transplant Recipients Receiving an Organ From EBV Positive Donors

Status:
NOT_YET_RECRUITING

Trial end date:
2027-02-01

Target enrollment:

Participant gender:

Summary

This clinical study will evaluate the safety and tolerability of an IDO-1 inhibitor in patients receiving a kidney transplant. The study includes individuals who have not previously been infected with Epstein-Barr virus (EBV) and who receive a kidney from a donor with prior EBV infection. Participants will receive the IDO-1 inhibitor or placebo in addition to standard medical care and will be monitored for side effects and other safety-related outcomes throughout the study.

Phase:

PHASE2

Details

Lead Sponsor:

University Hospital, Basel, Switzerland

Collaborator:

Hornet Therapeutics.